HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy
Background: Zoledronic acid, a bisphosphonate, increases bone mineral density (BMD), which can reduce clinical manifestations in osteogenesis imperfecta. This study investigates the impact of zoledronic acid therapy on the quality of life of pediatric patients with osteogenesis imperfecta. Methods:...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Airlangga
2023-10-01
|
| Series: | Journal Orthopaedi and Traumatology Surabaya |
| Subjects: | |
| Online Access: | https://e-journal.unair.ac.id/JOINTS/article/view/48362 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856480568213504 |
|---|---|
| author | Tri Wahyu Martanto Hamzah Rafly Rahman Patricia Maria Kurniawati |
| author_facet | Tri Wahyu Martanto Hamzah Rafly Rahman Patricia Maria Kurniawati |
| author_sort | Tri Wahyu Martanto |
| collection | DOAJ |
| description | Background: Zoledronic acid, a bisphosphonate, increases bone mineral density (BMD), which can reduce clinical manifestations in osteogenesis imperfecta. This study investigates the impact of zoledronic acid therapy on the quality of life of pediatric patients with osteogenesis imperfecta.
Methods: A retrospective analytical study was conducted on 16 pediatric patients with osteogenesis imperfecta who received intravenous zoledronic acid. Quality of life was assessed before and after therapy using the PedsQL 4.0 questionnaire. A paired t-test was used to analyze changes in each domain of the PedsQL 4.0. The results were expressed as an adjusted odds ratio with a 95% confidence interval. A p <0.05 was considered statistically significant.
Results: A significant increase was found in the children’s self-reported social performance (+12.083, p = 0.023) and proxy-reported physical performance, social performance, and total score (+14.844, p = 0.006; +10.625, p = 0.010; +10.364, p = 0.006, respectively). An insignificant increase was found in child-reported physical performance, school performance, and total score (+8.833, p = 0.148; +5.000, p = 0.359; +7.065, p = 0.115, respectively), and proxy-reported emotional and school performance (+2.500, p = 0.669; +6.250, p = 0.167, respectively). An insignificant decrease was found in child-reported emotional performance (-2.500, p = 0.669).
Conclusion: After receiving bisphosphonate therapy, pediatric patients with osteogenesis imperfecta experienced an increased quality of life. Physical and social aspects showed the greatest improvement. Emotional well-being showed the lowest increase in the child's perception, with a decrease in parent perception after therapy. |
| format | Article |
| id | doaj-art-231924146f7b4006b4711992e7bdd5bb |
| institution | Kabale University |
| issn | 2722-712X 2460-8742 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | Universitas Airlangga |
| record_format | Article |
| series | Journal Orthopaedi and Traumatology Surabaya |
| spelling | doaj-art-231924146f7b4006b4711992e7bdd5bb2025-02-12T07:27:30ZengUniversitas AirlanggaJournal Orthopaedi and Traumatology Surabaya2722-712X2460-87422023-10-01122495810.20473/joints.v12i2.2023.49-5846450HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid TherapyTri Wahyu Martanto0https://orcid.org/0000-0003-1273-8013Hamzah Rafly Rahman1https://orcid.org/0009-0002-7754-8907Patricia Maria Kurniawati2https://orcid.org/0009-0004-9825-7054Department of Orthopedics and Traumatology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Orthopedics and Traumatology, Dr. Soetomo General Academic Hospital, Surabaya, IndonesiaFaculty of Medicine, Universitas Airlangga, Surabaya, IndonesiaDepartment of Physical Medicine and Rehabilitation, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Physical Medicine and Rehabilitation, Dr. Soetomo General Academic Hospital, Surabaya, IndonesiaBackground: Zoledronic acid, a bisphosphonate, increases bone mineral density (BMD), which can reduce clinical manifestations in osteogenesis imperfecta. This study investigates the impact of zoledronic acid therapy on the quality of life of pediatric patients with osteogenesis imperfecta. Methods: A retrospective analytical study was conducted on 16 pediatric patients with osteogenesis imperfecta who received intravenous zoledronic acid. Quality of life was assessed before and after therapy using the PedsQL 4.0 questionnaire. A paired t-test was used to analyze changes in each domain of the PedsQL 4.0. The results were expressed as an adjusted odds ratio with a 95% confidence interval. A p <0.05 was considered statistically significant. Results: A significant increase was found in the children’s self-reported social performance (+12.083, p = 0.023) and proxy-reported physical performance, social performance, and total score (+14.844, p = 0.006; +10.625, p = 0.010; +10.364, p = 0.006, respectively). An insignificant increase was found in child-reported physical performance, school performance, and total score (+8.833, p = 0.148; +5.000, p = 0.359; +7.065, p = 0.115, respectively), and proxy-reported emotional and school performance (+2.500, p = 0.669; +6.250, p = 0.167, respectively). An insignificant decrease was found in child-reported emotional performance (-2.500, p = 0.669). Conclusion: After receiving bisphosphonate therapy, pediatric patients with osteogenesis imperfecta experienced an increased quality of life. Physical and social aspects showed the greatest improvement. Emotional well-being showed the lowest increase in the child's perception, with a decrease in parent perception after therapy.https://e-journal.unair.ac.id/JOINTS/article/view/48362bisphosphonate treatmenthuman and medicineosteogenesis imperfectapediatricquality of life |
| spellingShingle | Tri Wahyu Martanto Hamzah Rafly Rahman Patricia Maria Kurniawati HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy Journal Orthopaedi and Traumatology Surabaya bisphosphonate treatment human and medicine osteogenesis imperfecta pediatric quality of life |
| title | HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy |
| title_full | HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy |
| title_fullStr | HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy |
| title_full_unstemmed | HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy |
| title_short | HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy |
| title_sort | hrqol evaluation of pediatric osteogenesis imperfecta with zoledronic acid therapy |
| topic | bisphosphonate treatment human and medicine osteogenesis imperfecta pediatric quality of life |
| url | https://e-journal.unair.ac.id/JOINTS/article/view/48362 |
| work_keys_str_mv | AT triwahyumartanto hrqolevaluationofpediatricosteogenesisimperfectawithzoledronicacidtherapy AT hamzahraflyrahman hrqolevaluationofpediatricosteogenesisimperfectawithzoledronicacidtherapy AT patriciamariakurniawati hrqolevaluationofpediatricosteogenesisimperfectawithzoledronicacidtherapy |